Grail Publishes PATHFINDER 2 Presentation on Multi-Cancer Detection in Adults Aged 65 and Older

• Grail published a medical research presentation on PATHFINDER 2 results for its Galleri multi-cancer early detection test in adults aged 65 and older.
• The test detected 41.9% of cancers diagnosed within 12 months, with 99.44% specificity.
• Positive predictive value was 56.9%, with cancer confirmed in 116 of 204 participants testing positive.
• Adding Galleri to USPSTF grade A/B screening increased screen-detected cancers 9.9-fold, to 129 from 13.
• Among newly diagnosed primary cancers detected by Galleri, 69.3% were stage I-III; 84.3% of those received curative-intent treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.